2020
A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?
Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? American Journal On Addictions 2020, 29: 249-267. PMID: 32346932, PMCID: PMC7377168, DOI: 10.1111/ajad.13051.Peer-Reviewed Original ResearchMeSH KeywordsHumansNarcotic AntagonistsOpioid-Related DisordersOutcome Assessment, Health CareTreatment OutcomeConceptsUrine drug testsOpioid usePrimary outcomeOpioid use disorderTreatment studiesTreatment successUse disordersMedication treatment studiesOpioid treatment outcomesDifferent primary outcomesClinical trialsOpioid outcomesTreatment outcomesInclusion criteriaOutcome measuresLiterature reviewDrug testsOutcomesDisordersTreatmentReviewMedicationsMOUDStudyClinicians
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineHIV InfectionsHumansMethadoneNaltrexoneOpioid-Related DisordersTreatment OutcomeConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
2018
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2015
HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study
Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2015, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnti-HIV AgentsBlack or African AmericanBlack PeopleContinuity of Patient CareHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHomosexuality, MaleHumansInsurance, HealthKaplan-Meier EstimateMalePrisonersPrisonsRacial GroupsTreatment OutcomeYoung AdultConceptsBlack MSMHIV healthcare providersHIV treatment outcomesDisease management interventionsHIV/AIDS epidemicYoung Black MSMImpact of ageNon-black MSMHigher infection rateYoung HIVTreatment outcomesLarge cohortWorst HIVHIVHealth outcomesJail detaineesMale subgroupHealthcare providersInfection rateMulti-site studyMSMAIDS epidemicMenBlack menIntervention
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2013
Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severity
2012
Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior, AddictiveFemaleHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansIll-Housed PersonsInsurance, HealthMaleMiddle AgedMultivariate AnalysisPatient DischargePrevalencePrisonsProspective StudiesSeverity of Illness IndexSocial WorkSocioeconomic FactorsSubstance-Related DisordersTreatment OutcomeYoung AdultConceptsOpioid useJail detaineesPoor health outcomesSubstance use disordersSubstance abuse outcomesSubsequent drug useSubstance abuse treatmentOpioid relapseProspective cohortPsychiatric morbidityAppropriate diagnosisHigh prevalenceComplicate treatmentPsychiatric careUse disordersAlcohol severitySix monthsHealth outcomesDrug useHIVHealthcare accessAbuse treatmentSubstance abuseDrug relapseHealthcare outcomesRetention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineFemaleHIV InfectionsHumansMaleMiddle AgedNaloxoneOpioid-Related DisordersPrisonersProspective StudiesTreatment OutcomeConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroup
2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIV
2010
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care utilizationHIV treatment outcomesAlcohol use disorderPoor HIV treatment outcomesCare utilizationTreatment outcomesAntiretroviral therapyUse disordersImpact of AUDHealth service utilizationHIV/AIDSCD4 countHIV statusMedication adherenceService utilizationDATA SYNTHESISAnimal studiesElectronic databasesSystematic reviewAlcohol useTherapyPrimary articlesGoogle ScholarAdherenceOutcomesDAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions
Altice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDeoxycytidineDose-Response Relationship, DrugDrug Resistance, ViralEmtricitabineFemaleGenotypeHIV InfectionsHIV-1HumansLopinavirMaleMiddle AgedOrganophosphonatesPatient CompliancePyrimidinonesRandomized Controlled Trials as TopicRNA, ViralStavudineTenofovirTreatment OutcomeYoung Adult
2009
Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsDirectly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2005
Managing HIV/AIDS in correctional settings
Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports 2005, 2: 165-170. PMID: 16343373, DOI: 10.1007/s11904-005-0011-9.Peer-Reviewed Original ResearchMeSH KeywordsAntiretroviral Therapy, Highly ActiveHIV InfectionsHumansPrevalencePrisonersPrisonsTreatment OutcomeConceptsHIV/AIDSHIV care sitesActive antiretroviral therapyBurden of infectionEffective drug treatmentHIV risk behaviorsQuarter of peopleCorrectional health care systemIllicit drug useEffective case managementUntreated mental illnessHealth care systemPublic health officialsCorrectional settingsAntiretroviral therapyAdherence strategiesHIV outcomesComorbid conditionsManaging HIV/AIDSEffective therapyHIV epidemicHigh prevalenceCare sitesDrug treatmentHIV detection
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services